To include your compound in the COVID-19 Resource Center, submit it here.

AG-221: Phase Ib/II started

Celgene began an open-label, international Phase Ib/II trial to evaluate once-daily oral AG-221 or AG-120 with subcutaneous Vidaza azacitidine given for

Read the full 214 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE